As Burkholderia sp. 16 S rDNA gene (accession no. FJ667272.1) exhibited 92% identity to the corresponding gene of C. necator (accession no. CP000090.1), it is not surprising to find that the translated products of Burkholderia sp. PHA biosynthetic genes revealed identities to corresponding proteins of C. necator (63 89%).
No subjects exhibited adverse events after oseltamivir administration in the dose-finding pilot study.
ESBL were identified in 40 (27%) of the residents, however, no isolate exhibited resistance towards carbapenems.
No participant exhibited head motion of more than 1.5-mm translation or 1.5° angular rotation.
No variants exhibited changes in both first and second positions, nor in both second and fifth positions.
During the period of our study, no patients exhibited gastrointestinal bleeding, gastric pain or irritation, acne, psychiatric disturbances (including personality changes, irritability, euphoria, and mania), or cushingoid features.
Group 1, consisting of small adenomas with a slightly increased proportion of low-grade cases and no adenocarcinomas, exhibited expression profiles characterised by three overexpressed genes, that is, RACK1, PGC and ACBP.
As expected, no Columbia plants exhibited luciferase activity.
The higher molecular weight (longer side-chain) phthalates exhibited no toxic effects up to their limits of water solubility in the test systems.
Especially, in terms of emesis, about one-fourth of the patients felt grade 1 nausea for a short duration, but there were no patients that exhibited grade 2 nausea in our study.
The mixed SAM showed no phase segregation and exhibited human serum albumin resistance, particularly with an antibody-immobilized surface.
